Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis

Abstract

In the dynamic landscape of drug discovery, Computer-Aided Drug Design (CADD) emerges as a transformative force, bridging the realms of biology and technology. This paper overviews CADDs historical evolution, categorization into structure-based and ligand-based approaches, and its crucial role in rationalizing and expediting drug discovery. As CADD advances, incorporating diverse biological data and ensuring data privacy become paramount. Challenges persist, demanding the optimization of algorithms and robust ethical frameworks. Integrating Machine Learning and Artificial Intelligence amplifies CADDs predictive capabilities, yet ethical considerations and scalability challenges linger. Collaborative efforts and global initiatives, exemplified by platforms like Open-Source Malaria, underscore the democratization of drug discovery. The convergence of CADD with personalized medicine offers tailored therapeutic solutions, though ethical dilemmas and accessibility concerns must be navigated. Emerging technologies like quantum computing, immersive technologies, and green chemistry promise to redefine the future of CADD. The trajectory of CADD, marked by rapid advancements, anticipates challenges in ensuring accuracy, addressing biases in AI, and incorporating sustainability metrics. This paper concludes by highlighting the need for proactive measures in navigating the ethical, technological, and educational frontiers of CADD to shape a healthier, brighter future in drug discovery.

Hesperidin, a Potential Antiviral Agent against SARS-CoV-2: The Influence of Citrus Consumption on COVID-19 Incidence and Severity in China

“…ADMET prediction is essential for understanding the absorption, distribution, metabolism, excretion and toxicity profiles of hesperidin, which are key factors for predicting its usefulness as a therapeutic agent. In silico ADMET predictions provide early information on potential pharmacokinetics and toxicology in humans, which is critical for subsequent progression to clinical trials [41,42]. In silico studies conducted to investigate the potential of hesperidin as a therapeutic agent against SARS-CoV-2 have focused on several biological targets, including major protease (Mpro), spike protein (S protein), RdRp enzymes, human ACE2 receptor, nsp16 2 ′ -O-methyltransferase, PLpro, HR1 and RBD, RNA-dependent RNA polymerase (RdRp), TMPRSS2, the receptor-binding domain (RBD) of SARS-CoV-2 and viral proteins such as helicase (Hel), exoribonuclease (ExoN) and guanine-N7 methyltransferase.…”

Molecular Diagnostics of Cryptococcus spp. and Immunomics of Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome

“…Thus, it is important to continue studying the IRIS-like inflammation, expanding the omics portfolio to include genomics, metabolomics, and, moreover, dual host-pathogen RNA-sequencing methodologies [100,101]. In the pursuit of a comprehensive understanding of immune reconstitution inflammatory syndrome, a reliance on high-throughput laboratory methodologies in understanding antimicrobial resistance, computer-aided drug design, and the discovery of antimicrobial nanomaterials are imperative [1,[102][103][104]. Since IRIS-like inflammation is largely driven by microbial antigens, there has been an everincreasing need for novel machine learning models to predict neutralizing therapeutic peptides that would lessen immune response [105].…”

Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target

“…It involves the discovery of promising targets and the design of therapeutically effective and safe drugs against promising targets. Computer-aided drug design (CADD), employs a number of computational and statistical techniques to efficiently assess biological target selection and hit identification [ 13 , 14 ]. The process of drug development can be sped up by using advanced computational techniques.…”